Wnt-4 inhibits peridontitis by attenuating NF-kB

Wnt-4 通过减弱 NF-kB 抑制牙周炎

• 批准号: 8867872
• 负责人: CUN-YU WANG
• 金额: $ 38.76万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-08 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8867872
• 关键词: Adult; Age; Alveolar Bone Loss; Apoptosis; Attenuated; Basic Science; Bioinformatics; Biological; Biological Assay; Bone Resorption; Cardiovascular Diseases; Chronic; Clinical Trials; Complex; Diabetes Mellitus; Disease; EMSA; ERG gene; Foundations; Funding; Gelatinase B; Gene Expression; Genetic Models; Genetic Transcription; Genomics; Histology; Homo; I Kappa B-Alpha; IL8 gene; Immunoprecipitation; In Vitro; Inflammation; Inflammation Mediators; Inflammatory; Inflammatory Response; Intercellular adhesion molecule 1; Interleukin-6; Interstitial Collagenase; Ligands; Lipopolysaccharides; Luciferases; Mammalian Cell; Measures; Mediating; Molecular; Mus; NF-kappa B; Nuclear; Nuclear Translocation; Oral; Osteoblasts; Osteoclasts; Osteogenesis; Periodontal Diseases; Periodontitis; Phosphotransferases; Play; Porphyromonas gingivalis; Prevention; Protein Family; Proteins; RNA Interference; Recombinants; Regulation; Reporter; Reporting; Resolution; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Role; Signal Pathway; Signal Transduction; Systemic disease; TNFRSF5 gene; Testing; Tetanus Helper Peptide; Time; Tissues; Tooth Loss; Tooth structure; Transactivation; Transgenic Mice; Tumor Necrosis Factor-alpha; Western Blotting; Wild Type Mouse; Wnt-4 protein; aging population; alveolar bone; base; bone loss; cardiovascular disorder risk; chemokine; cyclooxygenase 2; cytokine; effective therapy; improved; in vivo; malignant mouth neoplasm; novel; novel therapeutics; osteoblast differentiation; p65; pathogen; prevent; receptor; repaired; screening; theories; therapeutic target; transcription factor

DESCRIPTION (provided by applicant): The long-term objectives of this competing renewal are to develop novel therapeutics for periodontitis by inhibiting nuclear factor-kappa B (NF-kB). Periodontitis is the most common inflammatory disease and often destroys periodontal tissues and alveolar bone, resulting in loss of tooth support. More importantly, growing evidence suggests that chronic periodontal inflammation is an important risk factor for cardiovascular disease, oral cancer, diabetes and other systemic diseases. Thus, it represents a significant public concern in the aging population. Multiple pro-inflammatory molecules, including tumor necrosis factor (TNF), interleulin-1 (IL-1), IL-6, IL-8, intercellular adhesion molecule-1, cyclooxygenase-2 (COX-2), matrix metalloproteinase (MMP)-1, and MMP-9, are associated with periodontal inflammation and bone loss. Basic science discoveries from our group and others have demonstrated that NF-kB is a master transcription factor that controls the expression of pro-inflammatory molecules. Using genomic and bioinformatic approaches, we have found that the majority of early-response genes induced by periodontal pathogens are dependent on NF-kB. Recently, we also discovered that the activation of NF-kB mediates the uncoupling of bone formation from bone resorption, providing a novel explanation for the compromised repair in periodontitis. Therefore, from the standpoint of developing novel therapeutics for periodontitis, targeting NF-kB may be more effective than single cytokines. In screening for novel molecules that inhibits NF-kB, unexpectedly, we discovered that Wnt-4 proteins inhibited periodontal inflammation and promoted repair in vitro and in vivo. Based on our preliminary studies, in this competing renewal, we hypothesize that Wnt-4 prevents periodontal inflammation and bone loss by attenuating NF-kB activation. Three specific aims are proposed to test our hypothesis. Aim 1 is to determine whether Wnt-4 prevents periodontal inflammation and alveolar bone loss by attenuating NF-kB activation in vivo. Aim 2 is to explore whether recombinant Wnt-4 proteins can inhibit the progression of periodontitis and maintains alveolar bone formation by attenuating NF-kB activation in vivo. Aim 3 is to explore the molecular mechanisms by which Wnt-4 suppresses NF-kB activation induced by inflammatory mediators. The results should provide an important proof-of-principal in the prevention and treatment of periodontitis by targeting NF-kB, and lay the important foundation for the clinical trials involving the IKK/NF-kB inhibitors.

描述（由申请人提供）：这种竞争更新的长期目标是通过抑制核因子-kappa B（NF-KB）来开发新的牙周炎治疗剂。牙周炎是最常见的炎症性疾病，经常会破坏牙周组织和肺泡骨，导致牙齿支撑失去。更重要的是，越来越多的证据表明，慢性牙周炎症是心血管疾病，口腔癌，糖尿病和其他全身性疾病的重要危险因素。因此，它代表着老龄化人口的重要公众关注。多种促炎分子，包括肿瘤坏死因子（TNF），唇素1（IL-1），IL-6，IL-8，胞内粘附分子-1，环氧酶-2（Cox-2）（Cox-2），基质金属蛋白酶（MMP）-1和MMP-9，and和MMMP-9，and and and and and and and and and and and and and and and and and and and and and and and and and and and and and and和mmmp-9，我们小组和其他人的基础科学发现表明，NF-KB是控制促炎分子表达的主要转录因子。使用基因组和生物信息学方法，我们发现牙周病原体诱导的大多数早期响应基因都取决于NF-KB。最近，我们还发现，NF-KB的激活介导了骨吸收的骨形成的解偶，从而为牙周炎修复受损提供了新的解释。因此，从开发新型牙周炎治疗剂的角度，靶向NF-KB可能比单个细胞因子更有效。在筛选抑制NF-KB的新分子时，我们发现Wnt-4蛋白抑制牙周炎症并在体外和体内促进修复。基于我们的初步研究，在这种竞争的续约中，我们假设WNT-4通过减弱NF-KB激活来防止牙周炎症和骨质流失。提出了三个特定目标来检验我们的假设。 AIM 1是确定Wnt-4是否通过减弱体内NF-KB激活来阻止牙周炎症和肺泡骨质流失。 AIM 2是探索重组Wnt-4蛋白是否可以通过在体内衰减NF-KB激活来抑制牙周炎的进展并保持肺泡骨形成。 AIM 3是探索Wnt-4抑制炎症介质引起的NF-KB激活的分子机制。结果应通过靶向NF-KB来预防和治疗牙周炎，并为涉及IKK/NF-KB抑制剂的临床试验奠定重要基础。